Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘mRNA vaccine’

It’s time for an extended update on the neoantigen space now that we have new clinical data to look at and discuss. There are a variety of approaches being evaluated in the clinic now, from adenoviral vectors to cell therapies to vaccines.

Indeed, we haven’t covered Moderna Therapeutics before as they were rather quiet in preclinical mode, but now they have some initial clinical data in cancer patients, we thought it would be nice to explore the company’s progress, as well as look at where they’re headed with their mRNA platform.

In the hotseat today, we take a look at the latest developments in the neoantigen vaccine field in terms of oncology settings and have an engaging company interview in the spotlight as well.

To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

One of the pioneers and leading entrepreneurs in the development of personalised cancer vaccines is Professor Ugur Sahin.

In addition to being CEO of the privately-held biopharmaceutical company, BioNTech, he holds an academic appointment at the University of Mainz and is Managing Director of the translational research institute TRON.

This makes Mainz the perfect location for a cancer immunotherapy conference. It’s also where the Association for Cancer Immunotherapy (CIMT) is located. They were the local organisers of the 3rd annual CRI-CIMT-EATI-AACR cancer immunotherapy conference that we recently attended along with over 1400 people from around the world.

One of the underlying themes of the meeting and the posters was the development of personalised cancer vaccines, which is why we’re doing an extended mini-series based on interviews we did in Germany with leaders in the field.

Prof Sahin is a busy man, but we tracked him down in the poster hall. Here’s a brief excerpt from the impromptu interview he kindly gave to BSB.

Subscribers can log-in to read more of the latest thought leader interview or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!